CURE is very pleased that Dr. LaMattina has agreed to return to our Biohaven series to discuss drug pricing transparency. This discussion is suitable for the general public, legislators, students, faculty, and healthcare stakeholders.
Susan Froshauer, Ph.D., President & CEO of CURE, President of CURE Innovations, LLC
Susan is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.
Dr. John LaMattina is the former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS.
Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of “Drug Truths: Dispelling the Myths About Phama R&D” and “Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?” He is also a contributor to Forbes.com.
He is currently a Senior Partner at PureTech Health and serves on the Board of Directors of Ligand Pharmaceuticals, Zafgen, Gelesis and Vedanta Biosciences.